EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement

Abdelrahman Saqr iD, Shen Cheng iD, Mahmoud Al-Kofahi iD, Christopher Staley iD, Pamala A Jacobson iD

Clinical Pharmacology & Therapeutics · 2025-12 · 118 (6) · 1477-1488

DOI: 10.1002/cpt.3740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 14.06.2025. Verfasst von Abdelrahman Saqr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Mycophenolic Acid, Gastrointestinal Microbiome, Enterohepatic Circulation, Immunosuppressive Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF). MPA undergoes glucuronidation to form MPA glucuronide (MPAG) which is deglucuronidated by bacterial β‐glucuronidases and reformed as MPA through enterohepatic circulation (EHC). We studied the stool microbiome effect on the pharmacokinetics of MPA, its metabolites, and EHC in hematopoietic cell transplant (HCT) recipients using a semi‐mechanistic population pharmacokinetic model. Microbiome communities were identified using correlation network analysis, and their impact on pharmacokinetics was assessed using full fixed‐effects modeling. Simulations were then conducted to evaluate MMF dosing regimens and to assess the impact of community abundance on EHC and MPA therapeutic target achievement. High abundance of Bacteroides uniformis ‐dominant and Bacteroides vulgatus ‐dominant communities was associated with higher EHC and an increase in MPA exposure. Low abundance of these communities was associated with a 52–80% and 4–83% lower EHC and MPA exposure, respectively. Simulations showed 70% of individuals with low abundance of these communities achieved the therapeutic target at the typical HCT MMF dose of 1,000 mg Q8 hours IV; however, ≥ 95% were within the therapeutic target at 1,250 mg Q8 hours or 1,750 mg Q12 hours. EHC accounted for 34% of the MPA area under the curve. Elimination of EHC reduced troughs by 100%. This work quantifies the microbiome’s effect on pharmacokinetics, paving the way for future microbiome‐informed dosing to optimize therapeutic target attainment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidGastrointestinal MicrobiomeEnterohepatic CirculationImmunosuppressive AgentsHumansMaleFemaleMiddle AgedHematopoietic Stem Cell TransplantationAdultModels, BiologicalFeces

Substanzen

Mycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.
  • Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

ORCID-Profile: Abdelrahman Saqr, Shen Cheng, Mahmoud Al-Kofahi, Christopher Staley, Pamala A Jacobson

Zitieren

APA

Saqr, A., Cheng, S., Al-Kofahi, M., Staley, C., & Jacobson, P. A. (2025). Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement. Clinical Pharmacology & Therapeutics, 118(6), 1477-1488. https://doi.org/10.1002/cpt.3740

Vancouver

Saqr A, Cheng S, Al-Kofahi M, Staley C, Jacobson PA. Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement. Clinical Pharmacology & Therapeutics. 2025;118(6):1477-1488. doi:10.1002/cpt.3740

BibTeX
@article{Saqr2025,
  author = {Saqr, Abdelrahman and Cheng, Shen and Al-Kofahi, Mahmoud and Staley, Christopher and Jacobson, Pamala A},
  title = {Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {6},
  pages = {1477--1488},
  doi = {10.1002/cpt.3740}
}
Kostenlos starten →